Medical/Pharmaceuticals
Oncoclínicas Group generated record earnings in the second quarter of 2023, R$309 million and a net profit of R$35 million
Efficient management of working capital explains a large part of the cash flow performance. Net income grew 51% (31% organically) while the Ebitda Ex-LTIP (excluding only the non-cash impact of the long-term incentive plan) reached R$268 million, 109% greater than the same period last year SÃO PA...
2023-08-16 19:00
1982
Record number of participants expected at Medlab Asia & Asia Health 2023
BANGKOK, Aug. 16, 2023 /PRNewswire/ -- Medlab Asia & Asia Health 2023, organised by Informa Markets and IMPACT Exhibition Management in collaboration with the Central Sterilizing Services Association, has officially opened to showcase the latest techniques and innovations in the healthcare and lab...
2023-08-16 16:08
2520
Nippon Express (Ireland) Opens New Warehouse in Dublin, Beginning Operations July 1
TOKYO, Aug. 16, 2023 /PRNewswire/ -- Nippon Express (Ireland) Ltd. (hereafter "NX Ireland"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a new warehouse, "Contract Logistics Center," inDublin city, beginning its operations onJuly 1. Logo: https://kyodonewsprwire.jp/img/2023...
2023-08-16 14:00
1855
Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines
'Fexuprazan,' Novel drug for Gastroesophageal Reflux Disease, starts its release inthe Philippines... The first case of overseas launch SEOUL, South Korea, Aug. 16, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Jeon Seng-ho, Lee Chang-jae) announced that 'Fuxuprazan' is officially launched i...
2023-08-16 13:00
2657
MGI Unveils Latest MGISP-NEX and MGIFLP-L50 Automation Systems at Medlab Asia & Asia Health 2023
BANGKOK, Thailand, Aug. 16, 2023 /PRNewswire/ -- MGI, a company committed to building core tools and technology to lead life science, today announced the global launch of MGISP-NEX and MGIFLP-L50 automation platforms at Medlab Asia & Asia Health 2023, taking place from 16-18 August at IMPACT E...
2023-08-16 11:00
2409
Charmacy Pharmaceutical Has Obtained the Provincial Capital Support
Future Expected Rapidly Growth HONG KONG, Aug. 16, 2023 /PRNewswire/ -- Charmacy Pharmaceutical Co., LTD. ( Charmacy Pharmaceutical, stock code: 2289.HK), as a leading private pharmaceutical distributor inSouth China, has been actively seeking strategic cooperation and resource complementary fro...
2023-08-16 09:00
3817
MedAlliance announces the completion of enrollment in SAVE Trial with SELUTION SLR for Treatment of AV Fistulas in Renal Dialysis Patients
GENEVA, Aug. 16, 2023 /PRNewswire/ -- MedAlliance has announced completion of patient enrollment in the SAVE Clinical Trial with the SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of failed AVF (arteriovenous fistulas) in renal dialysis patients. SELUTION SLR is a novel sirolimus-...
2023-08-16 08:00
1879
Transcenta to Present Three Study Results at ESMO 2023
SUZHOU, China, Aug. 16, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it is going to ...
2023-08-16 08:00
1937
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues Gross margin increases to 80.3%; balance sheet remains strong GAITHERSBURG, Md., Aug. 16, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biop...
2023-08-16 05:00
2739
CStone Pharmaceuticals Reports 2023 Interim Results and Updates
* The total revenue was RMB 261.5 million for the six months ended June 30, 2023. The sales of pharmaceutical products revenue was RMB 246.9 million, representing a growth rate of 53% compared to the same period last year. Commercial gross profit margin improved from 47% to 59%. * Healthy fin...
2023-08-15 22:33
3994
Everest Medicines' Partner Venatorx Receives FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI)
SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase in...
2023-08-15 20:19
2837
Leading Asia Pacific Biopharmas Power Digital Engagement with Veeva CRM
Eighteen of the top 20 biopharmas standardize with Veeva to build meaningful
customer relationships
SINGAPORE, Aug. 15, 2023 /PRNewswire/ -- Veeva Systems
2023-08-15 09:00
3132
TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan
Non-profit drug developer partners with leading manufacturer of medicine in Pakistan NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medici...
2023-08-14 21:30
1851
UMP Introduces Artificial Intelligence Technology for Enhanced Chest X-Ray Analysis Efficiency
HONG KONG, Aug. 14, 2023 /PRNewswire/ -- UMP Healthcare Holdings Limited ("UMP " or the "Group", stock code: 722.HK) is pleased to announce the signing of a memorandum of understanding (MOU) withImsight Technology Company Limited, specialised in providing artificial intelligence (AI) medical imag...
2023-08-14 15:45
2201
Kelun-Biotech announces that a Phase III clinical trial of core product SKB264 (MK-2870, TROP2-ADC) in patients with unresectable locally advanced, recurrent or metastatic TNBC who have failed second-line or above prior standard of care has met its primary endpoint
CHENGDU, China, Aug. 14, 2023 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. ("Kelun-Biotech", HKEX: 6990.HK) announced today that its innovative TROP2-ADC (SKB264, also known as MK-2870) met the primary endpoint in the randomized, controlled, open-label, multi-center Phase III ...
2023-08-14 12:50
3694
Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach
PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a$1M contract spanning two years (HHSF223018186...
2023-08-11 21:14
3336
Move Aside Anti-Ageing, It's Age Reversal We're Talking Now
SINGAPORE, Aug. 11, 2023 /PRNewswire/ -- In the realm of medical progress, the horizon extends far beyond the battle against diseases. Now, the concept of "age reversal" — not merely slowing down or halting ageing — stands as a tangible reality. However, the validity and accuracy of ageing measur...
2023-08-11 13:49
2067
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...
2023-08-11 11:14
1983
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China
- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broadening coverage and improving access of the drug to patients in the mainland ofChina - Antengene to receive up to RMB200 million in upfront payments,...
2023-08-11 08:00
2860
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...
2023-08-11 07:18
2038
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8288
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7685